Profil
Charity D.
Scripture served as the Chief Development Officer at Bellicum Pharmaceuticals, Inc. from 2019 to 2024.
Prior to that, she worked as the Vice President of Business and Development Operations at ACELYRIN, Inc. She completed her undergraduate degree at Hamilton College (New York), her graduate degree at Dartmouth Medical School, and her doctorate at the University of North Carolina at Chapel Hill.
Anciens postes connus de Charity Scripture
| Sociétés | Poste | Fin |
|---|---|---|
| BELLICUM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 23/02/2024 |
| ACELYRIN, INC. | Corporate Officer/Principal | - |
Formation de Charity Scripture
| Hamilton College (New York) | Undergraduate Degree |
| Dartmouth Medical School | Graduate Degree |
| University of North Carolina at Chapel Hill | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ACELYRIN, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Bellicum Pharmaceuticals, Inc.
 Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
